Progression to AIDS and death in the era of HAART

AIDS

Volumn 20, Issue 7, 2006, Pages 1067-1068

  Hill, Andrew ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

AIDS; CD4 cell count; HAART; Mortality

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADVERSE DRUG REACTION; CD4 LYMPHOCYTE COUNT; DEATH; DISEASE COURSE; DRUG EFFICACY; DRUG USE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MORTALITY; NOTE; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; DISEASE PROGRESSION; HUMANS; RNA, VIRAL;

EID: 33646379385     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000222082.36787.9a     Document Type: Note

References (5)

1. Moore DM, Hogg RS, Chan K, Tyndall M, Yip B, Montaner JSG. Disease progression in patients with virological suppression in response to HAART is associated with the degree of immunological response. AIDS 2006; 20:371-377.
2. Chadborn T, Baster K, Delpech V, Sabin C, Sinka K, Rice B, et al. No time to wait: how many HIV-infected homosexual men are diagnosed late and consequently die? AIDS 2005; 19:513-520.
3. Chen R, Westfall A, Cloud G, Chatham A, Acosta E, Raper J, et al. Long-term survival alters initiation of antiretroviral therapy. Eighth Conference on Retroviruses and Opportunistic Infections. Chicago, February 2001 [abstract 341].
4. The PLATO Collaboration. Predictors of trend in CD4-positive T-cell count and mortality among HIV-1 infected individuals with virological failure to all three antiretroviral drug classes. Lancet 2004; 364: 51-62
5. Olsen CH, Gatell J, Ledergerber B, Katlama C, Friis-Moller N, Weber J, et al. for the EuroSIDA Study Group. Risk of AIDS and death at given HIV-RNA and CD4 cell count, in relation to specific antiretroviral drugs in the regimen. AIDS 2005; 19:319-330.